This blog is all about current FDA approved drugs to treat the hepatitis C virus (HCV) with a focus on treating HCV according to genotype, using information extracted from peer-reviewed journals, liver meetings/conferences, and interactive learning activities.
Risk Of Developing Liver Cancer After HCV Treatment
▼
Monday, April 28, 2014
Video - Pricey Hepatitis C Pill Sovaldi Rattles Medicaid Programs
Pricey Hepatitis Pill Sovaldi Rattles Medicaid Programs
April 28th, 2014 by ABMN Staff
Medicaid health insurance programs for the poor are grappling with how to pay for the costly Hepatitis C treatment Sovaldi, which costs $1,000 a pill and is running up a huge tab for states already grappling with myriad health and general budgetary issues. The costs are hitting Medicaid programs extraordinarily hard because the population of patients in need of Sovaldi tend to have low incomes and wouldn’t be able to afford it without the government insurance.
“Pricey Hepatitis Pill Sovaldi Rattles Medicaid Programs” is categorized as “world”. This video was licensed from Grab Networks. For additional video content, click the “video” tab at the top of this page.
What is this cost compared to the cost of failure? How many unsuccessful HCV treatments has Medicaid paid for so far? How much has been paid for liver transplants? Hospitalizations due to HCV? Liver failure? Surely, the cost of an effective CURE is less than the cost of multiple failures, especially related to Interferon based failures where side effects are significant.
ReplyDeleteHCV is very costly, when end stage sets in.
ReplyDelete